IHC
Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics
By analyzing blood serum proteomics alongside gastric tumors' omics profiles, researchers found immune features coinciding with treatment response and survival.
NeoGenomics, ImmunoGen Ink Testing Deal for Newly Approved Folate Receptor Drug
The pharma firm will cover the cost for eligible ovarian cancer patients to be tested using the companion diagnostic to its new drug Elahere.
Immunotherapy Response Features Identified in Pancreatic Cancer Microenvironment
Researchers compared tumor microenvironment features in pancreatic ductal adenocarcinoma cases receiving an allogeneic vaccine with or without anti-PD-1 treatment.
The firm is aiming to commercialize its OncoPrism assay in 2023 as a laboratory-developed test to identify head and neck cancer patients eligible for checkpoint inhibitors.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.